BioCentury | May 23, 2019
Tools & Techniques
As polygenic risk scores mature, opportunities emerge for disease interception
...from marketed products,” rather than investigational drugs, he said. Joseph Pickrell, CEO of test developer Gencove Inc....
...Society of Clinical Oncology (ASCO), Alexandria, Va. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Color, Burlingame, Calif. Gencove Inc....
...Low-density lipoprotein receptor PCSK9 - Proprotein convertase subtilisin/kexin type 9 Karen Tkach Tuzman, Associate Editor Celgene Corp. Color Gencove Inc. Johns...
...Society of Clinical Oncology (ASCO), Alexandria, Va. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Color, Burlingame, Calif. Gencove Inc....
...Low-density lipoprotein receptor PCSK9 - Proprotein convertase subtilisin/kexin type 9 Karen Tkach Tuzman, Associate Editor Celgene Corp. Color Gencove Inc. Johns...